EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design, Synthesis, and Biological Evaluation of Novel Triazine‐Based Dual Histone Deacetylase/phosphatidylinositol 3‐kinase Inhibitors for Breast Cancer Therapy

Lara Luzietti, Gustavo Salgado Pires, Ana Ryan, Crisamie Regidor, Matthew Hiller, Danilo Sarti, Tríona Ní Chonghaile, Pedro de Sena Murteira Pinheiro, Damir Varešlija iD, Daniel Alencar Rodrigues iD

ChemMedChem · 28.04.2026 · 21 (8)

DOI: 10.1002/cmdc.202501041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 25.04.2026. Verfasst von Lara Luzietti und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Biomolecular Sciences (PBS), Royal College of Surgeons in Ireland, Dublin, Ireland. Hauptthemen laut MEDLINE: Triazines, Drug Design, Histone Deacetylase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Ireland, Breast Cancer Now, Irish Research Council for Science, Engineering and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is the most frequently diagnosed malignancy and a leading cause of cancer‐related mortality among women worldwide. Triple‐negative breast cancer (TNBC) poses a major clinical challenge due to its aggressive nature, limited therapeutic options, and high propensity for drug resistance. Dysregulation of the phosphatidylinositol 3‐kinase (PI3K)/AKT/mTOR and histone deacetylase (HDAC) signaling pathways has been implicated in TNBC progression and therapeutic resistance, highlighting their potential as combinatorial targets. In this study, we report the design, synthesis, and biological evaluation of a novel series of triazine‐based multitarget inhibitors aimed at the dual inhibition of PI3K and HDAC. Among the synthesized compounds, 5b and 5f demonstrated the most promising profiles, exhibiting low nanomolar IC 50 values against HDAC6 (2.33 and 6.02 nM) and PI3Kα (17.5 and 236 nM), respectively. Both compounds reduced cell viability in breast cancer cell lines, with IC 50 values below 5 µM in MDA‐MB‐231 cells. Western blot analysis confirmed inhibition of HDAC and PI3K signaling in treated cells. Molecular docking and dynamics simulations further revealed stable binding modes and favorable interactions within the active sites of both targets. Overall, 5b and 5f represent promising lead candidates for further optimization toward the development of novel dual HDAC/PI3K inhibitors with potential application in TNBC therapy, as evaluated in TNBC‐relevant models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriazinesDrug DesignHistone Deacetylase InhibitorsAntineoplastic AgentsPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsHumansStructure-Activity RelationshipDrug Screening Assays, AntitumorFemaleCell SurvivalMolecular StructureCell ProliferationDose-Response Relationship, DrugMolecular Docking SimulationPhosphatidylinositol 3-KinasesCell Line, TumorHistone DeacetylasesBreast NeoplasmsPhosphatidylinositol 3-KinaseMDA-MB-231 Cells

Stichwörter der Autor:innen

breast cancercancerhistone deacetylase (HDAC)phosphatidylinositol 3‐kinase (PI3K)triazine

Substanzen

TriazinesHistone Deacetylase InhibitorsAntineoplastic AgentsPhosphoinositide-3 Kinase InhibitorsPhosphatidylinositol 3-KinasesHistone DeacetylasesProtein Kinase InhibitorsPhosphatidylinositol 3-Kinase

Autor:innen und Institutionen

  • School of Pharmacy and Biomolecular Sciences (PBS), Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Cidade Universitária, Rio de Janeiro, Brazil.
  • Programa de Pós-Graduação em Farmacologia e Química Medicinal (PPGFQM), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Cidade Universitária, Rio de Janeiro, Brazil.
  • Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland.

ORCID-Profile: Damir Varešlija, Daniel Alencar Rodrigues

Förderung

  • Research Ireland
  • Breast Cancer Now
  • Irish Research Council for Science, Engineering and Technology
  • INCT-INOFAR
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
  • RCSI
  • RCSI-Fulbright
  • IRCSET

Zitieren

APA

Luzietti, L., Pires, G. S., Ryan, A., Regidor, C., Hiller, M., Sarti, D., Ní Chonghaile, T., Pinheiro, P. S. M., Varešlija, D., & Rodrigues, D. A. (2026). Design, Synthesis, and Biological Evaluation of Novel Triazine‐Based Dual Histone Deacetylase/phosphatidylinositol 3‐kinase Inhibitors for Breast Cancer Therapy. ChemMedChem, 21(8). https://doi.org/10.1002/cmdc.202501041

Vancouver

Luzietti L, Pires GS, Ryan A, Regidor C, Hiller M, Sarti D, et al. Design, Synthesis, and Biological Evaluation of Novel Triazine‐Based Dual Histone Deacetylase/phosphatidylinositol 3‐kinase Inhibitors for Breast Cancer Therapy. ChemMedChem. 2026;21(8). doi:10.1002/cmdc.202501041

BibTeX
@article{Luzietti2026,
  author = {Luzietti, Lara and Pires, Gustavo Salgado and Ryan, Ana and Regidor, Crisamie and Hiller, Matthew and Sarti, Danilo and Ní Chonghaile, Tríona and Pinheiro, Pedro de Sena Murteira and Varešlija, Damir and Rodrigues, Daniel Alencar},
  title = {Design, Synthesis, and Biological Evaluation of Novel Triazine‐Based Dual Histone Deacetylase/phosphatidylinositol 3‐kinase Inhibitors for Breast Cancer Therapy},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {8},
  doi = {10.1002/cmdc.202501041}
}
Kostenlos starten →